HRP20210277T1 - Pripravak za kontroliranu stimulaciju jajnika - Google Patents
Pripravak za kontroliranu stimulaciju jajnika Download PDFInfo
- Publication number
- HRP20210277T1 HRP20210277T1 HRP20210277TT HRP20210277T HRP20210277T1 HR P20210277 T1 HRP20210277 T1 HR P20210277T1 HR P20210277T T HRP20210277T T HR P20210277TT HR P20210277 T HRP20210277 T HR P20210277T HR P20210277 T1 HRP20210277 T1 HR P20210277T1
- Authority
- HR
- Croatia
- Prior art keywords
- product
- recombinant human
- fsh
- patient
- dose
- Prior art date
Links
- 230000002611 ovarian Effects 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 claims 11
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 claims 11
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 5
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 4
- 208000000509 infertility Diseases 0.000 claims 3
- 230000036512 infertility Effects 0.000 claims 3
- 231100000535 infertility Toxicity 0.000 claims 3
- 230000009450 sialylation Effects 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- -1 alkali metal cation Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (12)
1. Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za uporabu u liječenju neplodnosti kod pacijenta s razinom AMH u serumu < 15 pmol/L, pri čemu se proizvod daje u dozi od, ili dozi ekvivalentnoj, 11-13 µg rekombinantnog ljudskog FSH dnevno, pri čemu proizvod nadalje sadrži hCG.
2. Proizvod za uporabu prema patentnom zahtjevu 1 naznačen time što se proizvod daje u dozi od, ili dozi ekvivalentnoj, 12 µg rekombinantnog ljudskog FSH dnevno.
3. Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za uporabu u liječenju neplodnosti kod pacijenta s razinom AMH u serumu ≥ 15 pmol/L, pri čemu se proizvod daje u dozi od, ili dozi ekvivalentnoj, 0,09-0,19 µg rekombinantnog ljudskog FSH po kg tjelesne težine pacijenta dnevno, pri čemu proizvod nadalje sadrži hCG.
4. Proizvod za uporabu prema patentnom zahtjevu 3 u liječenju pacijenta koji ima razinu AMH u serumu od 15 do 24,9 pmol/L, pri čemu se proizvod daje u dozi od ili dozi ekvivalentnoj 0,14 do 0,19 µg rekombinantnog ljudskog FSH po kg tjelesne težine pacijenta dnevno.
5. Proizvod za uporabu prema patentnom zahtjevu 3 u liječenju pacijenta koji ima razinu AMH u serumu od 25 do 34,9 pmol/L, pri čemu se proizvod daje u dozi od ili dozi ekvivalentnoj, 0,11 do 0,14 µg rekombinantnog ljudskog FSH po kg tjelesne težine pacijenta dnevno.
6. Proizvod za uporabu prema patentnom zahtjevu 3 u liječenju pacijenta koji ima razinu AMH u serumu od ≥ 35 pmol/L, pri čemu se proizvod daje u dozi od ili dozi ekvivalentnoj, 0,10 do 0,11 µg ljudskog derivata rekombinantnog ljudskog FSH po kg tjelesne težine pacijenta dnevno.
7. Proizvod za uporabu prema bilo kojem prethodnom patentnom zahtjevu naznačen time što je rekombinantni ljudski FSH rekombinantni ljudski FSH koji uključuje α2, 3- i α2, 6-sialilaciju.
8. Proizvod za uporabu prema patentnom zahtjevu 7 naznačen time što 1 % do 50% ukupne sialilacije je α2, 6-sializacija, i 50% do 99% ukupne sialilacije je α2,3-sializacija.
9. Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) naznačen time što je za uporabu u liječenju neplodnosti u skladu s bilo kojim od prethodnih zahtjeva, pri čemu proizvod nadalje sadrži sol koja sadrži farmaceutski prihvatljiv kation alkalijskog metala odabran iz skupine koju čine soli Na+- ili K+- ili njihova kombinacija.
10. Proizvod za uporabu prema bilo kojem prethodnom patentnom zahtjevu naznačen time što je hCG rekombinantni hCG.
11. Proizvod za uporabu prema bilo kojem prethodnom patentnom zahtjevu naznačen time što su FSH i hCG za zajedničku primjenu.
12. Proizvod za uporabu prema bilo kojem od zahtjeva 1 do 10 naznačen time što su FSH i hCG za odvojenu primjenu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11176803 | 2011-08-08 | ||
| EP19164277.6A EP3566712B1 (en) | 2011-08-08 | 2012-08-08 | Composition for controlled ovarian stimulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210277T1 true HRP20210277T1 (hr) | 2021-04-02 |
Family
ID=46785372
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230607TT HRP20230607T1 (hr) | 2011-08-08 | 2012-08-08 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20240420TT HRP20240420T1 (hr) | 2011-08-08 | 2012-08-08 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20160145TT HRP20160145T1 (hr) | 2011-08-08 | 2016-02-09 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20181639TT HRP20181639T1 (hr) | 2011-08-08 | 2018-10-10 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20190023TT HRP20190023T1 (hr) | 2011-08-08 | 2019-01-03 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20191437 HRP20191437T1 (hr) | 2011-08-08 | 2019-08-08 | Sastav za kontroliranu stimulaciju jajnika |
| HRP20210277TT HRP20210277T1 (hr) | 2011-08-08 | 2021-02-18 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20210722TT HRP20210722T1 (hr) | 2011-08-08 | 2021-05-10 | Pripravak za kontroliranu stimulaciju jajnika |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230607TT HRP20230607T1 (hr) | 2011-08-08 | 2012-08-08 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20240420TT HRP20240420T1 (hr) | 2011-08-08 | 2012-08-08 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20160145TT HRP20160145T1 (hr) | 2011-08-08 | 2016-02-09 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20181639TT HRP20181639T1 (hr) | 2011-08-08 | 2018-10-10 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20190023TT HRP20190023T1 (hr) | 2011-08-08 | 2019-01-03 | Pripravak za kontroliranu stimulaciju jajnika |
| HRP20191437 HRP20191437T1 (hr) | 2011-08-08 | 2019-08-08 | Sastav za kontroliranu stimulaciju jajnika |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210722TT HRP20210722T1 (hr) | 2011-08-08 | 2021-05-10 | Pripravak za kontroliranu stimulaciju jajnika |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9694052B2 (hr) |
| EP (9) | EP3395357B1 (hr) |
| JP (5) | JP6161609B2 (hr) |
| KR (7) | KR102111514B1 (hr) |
| CN (2) | CN107281470A (hr) |
| AR (1) | AR087476A1 (hr) |
| AU (3) | AU2012293647B2 (hr) |
| BR (2) | BR112014002884A2 (hr) |
| CA (1) | CA2844282A1 (hr) |
| CY (1) | CY1117214T1 (hr) |
| DK (8) | DK2821080T3 (hr) |
| ES (7) | ES2742163T3 (hr) |
| FI (2) | FI3756681T3 (hr) |
| HK (2) | HK1204923A1 (hr) |
| HR (8) | HRP20230607T1 (hr) |
| HU (7) | HUE027674T2 (hr) |
| IL (2) | IL300380A (hr) |
| JO (1) | JO3092B1 (hr) |
| LT (7) | LT3395357T (hr) |
| MX (2) | MX348981B (hr) |
| PL (8) | PL3395357T3 (hr) |
| PT (6) | PT2821080T (hr) |
| RS (8) | RS65485B1 (hr) |
| RU (2) | RU2739037C3 (hr) |
| SA (1) | SA112330762B1 (hr) |
| SI (7) | SI3646881T1 (hr) |
| SM (1) | SMT201600038B (hr) |
| TR (2) | TR201900071T4 (hr) |
| TW (2) | TWI555530B (hr) |
| WO (1) | WO2013020996A1 (hr) |
| ZA (2) | ZA201400952B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| WO2016102436A1 (en) * | 2014-12-22 | 2016-06-30 | F. Hoffmann-La Roche Ag | Cmp-dependent sialidase activity |
| PL3283097T3 (pl) * | 2015-04-17 | 2020-10-19 | Ferring B.V. | FSH do leczenia niepłodności |
| ES2770860T3 (es) | 2015-06-26 | 2020-07-03 | Ferring Bv | Métodos de purificación y/o inactivación viral |
| US20180264086A1 (en) * | 2015-09-17 | 2018-09-20 | Glycotope Gmbh | Mammalian follicle-stimulating hormone composition with increased stability |
| TWI778979B (zh) | 2016-09-30 | 2022-10-01 | 瑞士商麥歐文科學有限公司 | 治療女性不孕症之方法 |
| MA50034B1 (fr) | 2017-09-01 | 2022-02-28 | Ferring Bv | Composition de stimulation ovarienne contrôlée |
| JP2021522268A (ja) | 2018-04-30 | 2021-08-30 | フェリング ベスローテン フェンノートシャップ | 制御された卵巣刺激のための組成物 |
| EP3866833A1 (en) | 2018-10-17 | 2021-08-25 | Ferring BV | Compositions and methods for controlled ovarian stimulation |
| US11576920B2 (en) | 2019-03-18 | 2023-02-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
| CN110841060A (zh) * | 2019-11-21 | 2020-02-28 | 上海交通大学 | Choriogonadotropin alfa在治疗多囊卵巢综合征中的应用 |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
| WO2023186331A1 (en) | 2022-04-01 | 2023-10-05 | Ferring B.V. | Mixed protocol for treatment of infertility |
| WO2023227761A1 (en) | 2022-05-26 | 2023-11-30 | Ferring B.V. | Compositions and methods for treatment of infertility in males |
| WO2024008971A1 (en) | 2022-07-08 | 2024-01-11 | Ferring B.V. | Compositions and methods for intrauterine insemination (iui) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL122732A0 (en) | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| EP1074265A1 (en) * | 1999-08-03 | 2001-02-07 | Erasmus Universiteit Rotterdam | Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility |
| EA007030B1 (ru) * | 2001-10-22 | 2006-06-30 | Апплайд Резеч Системз Арс Холдинг Н.В. | Гонадотропины для фолликулогенеза |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| US8501719B2 (en) * | 2005-11-08 | 2013-08-06 | American Infertility Of New York | Androgen treatment in females |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| WO2012016576A1 (en) | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| FI2621517T4 (fi) * | 2010-09-29 | 2024-01-03 | Ferring Bv | Koostumus käytettäväksi hedelmättömyyden hoidossa |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
-
2012
- 2012-07-18 JO JOP/2012/0197A patent/JO3092B1/ar active
- 2012-07-23 TW TW101126453A patent/TWI555530B/zh active
- 2012-07-23 TW TW105124123A patent/TWI657822B/zh active
- 2012-08-07 SA SA112330762A patent/SA112330762B1/ar unknown
- 2012-08-07 AR ARP120102883A patent/AR087476A1/es not_active Application Discontinuation
- 2012-08-08 ES ES18167552T patent/ES2742163T3/es active Active
- 2012-08-08 EP EP18167552.1A patent/EP3395357B1/en active Active
- 2012-08-08 BR BR112014002884A patent/BR112014002884A2/pt not_active Application Discontinuation
- 2012-08-08 HU HUE12753675A patent/HUE027674T2/en unknown
- 2012-08-08 SI SI201231921T patent/SI3646881T1/sl unknown
- 2012-08-08 PL PL18167552T patent/PL3395357T3/pl unknown
- 2012-08-08 SI SI201231884T patent/SI3566712T1/sl unknown
- 2012-08-08 ES ES14184409T patent/ES2704878T3/es active Active
- 2012-08-08 DK DK14184409.2T patent/DK2821080T3/en active
- 2012-08-08 PT PT14184409T patent/PT2821080T/pt unknown
- 2012-08-08 SI SI201232033T patent/SI3756681T1/sl unknown
- 2012-08-08 EP EP21207717.6A patent/EP4005588B1/en active Active
- 2012-08-08 HR HRP20230607TT patent/HRP20230607T1/hr unknown
- 2012-08-08 HR HRP20240420TT patent/HRP20240420T1/hr unknown
- 2012-08-08 EP EP23208228.9A patent/EP4306174A3/en active Pending
- 2012-08-08 RS RS20240487A patent/RS65485B1/sr unknown
- 2012-08-08 LT LTEP18167552.1T patent/LT3395357T/lt unknown
- 2012-08-08 PL PL19164277T patent/PL3566712T3/pl unknown
- 2012-08-08 ES ES19213649T patent/ES2884947T3/es active Active
- 2012-08-08 ES ES20186935T patent/ES2950911T3/es active Active
- 2012-08-08 HU HUE20186935A patent/HUE062640T2/hu unknown
- 2012-08-08 WO PCT/EP2012/065507 patent/WO2013020996A1/en active Application Filing
- 2012-08-08 RS RS20230518A patent/RS64328B1/sr unknown
- 2012-08-08 LT LTEP19164277.6T patent/LT3566712T/lt unknown
- 2012-08-08 IL IL300380A patent/IL300380A/en unknown
- 2012-08-08 LT LTEP17154031.3T patent/LT3195875T/lt unknown
- 2012-08-08 CN CN201710306350.4A patent/CN107281470A/zh active Pending
- 2012-08-08 KR KR1020197024335A patent/KR102111514B1/ko active IP Right Grant
- 2012-08-08 PL PL14184409T patent/PL2821080T3/pl unknown
- 2012-08-08 SI SI201230438T patent/SI2741763T1/sl unknown
- 2012-08-08 US US14/237,697 patent/US9694052B2/en active Active
- 2012-08-08 LT LTEP20186935.1T patent/LT3756681T/lt unknown
- 2012-08-08 JP JP2014524372A patent/JP6161609B2/ja active Active
- 2012-08-08 LT LTEP14184409.2T patent/LT2821080T/lt unknown
- 2012-08-08 LT LTEP19213649.7T patent/LT3646881T/lt unknown
- 2012-08-08 RS RS20210603A patent/RS61843B1/sr unknown
- 2012-08-08 DK DK18167552.1T patent/DK3395357T3/da active
- 2012-08-08 KR KR1020217023662A patent/KR102353144B1/ko active IP Right Grant
- 2012-08-08 HU HUE19213649A patent/HUE054312T2/hu unknown
- 2012-08-08 RS RS20190006A patent/RS58198B1/sr unknown
- 2012-08-08 PT PT201869351T patent/PT3756681T/pt unknown
- 2012-08-08 PL PL17154031T patent/PL3195875T3/pl unknown
- 2012-08-08 KR KR1020197036505A patent/KR20190140098A/ko not_active IP Right Cessation
- 2012-08-08 RS RS20191038A patent/RS59107B1/sr unknown
- 2012-08-08 HU HUE18167552 patent/HUE044610T2/hu unknown
- 2012-08-08 TR TR2019/00071T patent/TR201900071T4/tr unknown
- 2012-08-08 PT PT17154031T patent/PT3195875T/pt unknown
- 2012-08-08 EP EP19164277.6A patent/EP3566712B1/en active Active
- 2012-08-08 DK DK12753675.3T patent/DK2741763T3/da active
- 2012-08-08 SI SI201231653T patent/SI3395357T1/sl unknown
- 2012-08-08 AU AU2012293647A patent/AU2012293647B2/en active Active
- 2012-08-08 PT PT18167552T patent/PT3395357T/pt unknown
- 2012-08-08 PL PL19213649T patent/PL3646881T3/pl unknown
- 2012-08-08 RS RS20210425A patent/RS61672B1/sr unknown
- 2012-08-08 MX MX2014001489A patent/MX348981B/es active IP Right Grant
- 2012-08-08 PL PL21207717.6T patent/PL4005588T3/pl unknown
- 2012-08-08 RS RS20160080A patent/RS54561B1/en unknown
- 2012-08-08 CA CA2844282A patent/CA2844282A1/en active Pending
- 2012-08-08 PT PT192136497T patent/PT3646881T/pt unknown
- 2012-08-08 EP EP14184409.2A patent/EP2821080B1/en active Active
- 2012-08-08 EP EP17154031.3A patent/EP3195875B1/en active Active
- 2012-08-08 ES ES17154031.3T patent/ES2692774T3/es active Active
- 2012-08-08 CN CN201280038831.7A patent/CN103732243A/zh active Pending
- 2012-08-08 PT PT212077176T patent/PT4005588T/pt unknown
- 2012-08-08 DK DK21207717.6T patent/DK4005588T3/da active
- 2012-08-08 FI FIEP20186935.1T patent/FI3756681T3/fi active
- 2012-08-08 PL PL12753675T patent/PL2741763T3/pl unknown
- 2012-08-08 EP EP20186935.1A patent/EP3756681B1/en active Active
- 2012-08-08 KR KR1020237004855A patent/KR20230024442A/ko not_active Application Discontinuation
- 2012-08-08 HU HUE14184409A patent/HUE041769T2/hu unknown
- 2012-08-08 ES ES12753675.3T patent/ES2562648T3/es active Active
- 2012-08-08 BR BR122020001644-2A patent/BR122020001644B1/pt active IP Right Grant
- 2012-08-08 HU HUE19164277A patent/HUE053716T2/hu unknown
- 2012-08-08 TR TR2019/11269T patent/TR201911269T4/tr unknown
- 2012-08-08 RU RU2017106756A patent/RU2739037C3/ru active Protection Beyond IP Right Term
- 2012-08-08 DK DK17154031.3T patent/DK3195875T3/en active
- 2012-08-08 ES ES19164277T patent/ES2871405T3/es active Active
- 2012-08-08 KR KR1020207029774A patent/KR20200121918A/ko not_active Application Discontinuation
- 2012-08-08 LT LTEP21207717.6T patent/LT4005588T/lt unknown
- 2012-08-08 EP EP19213649.7A patent/EP3646881B1/en active Active
- 2012-08-08 SI SI201231398T patent/SI3195875T1/sl unknown
- 2012-08-08 DK DK19164277.6T patent/DK3566712T3/da active
- 2012-08-08 RU RU2014102924A patent/RU2613324C3/ru active Protection Beyond IP Right Term
- 2012-08-08 PL PL20186935.1T patent/PL3756681T3/pl unknown
- 2012-08-08 SI SI201231493T patent/SI2821080T1/sl unknown
- 2012-08-08 DK DK20186935.1T patent/DK3756681T3/da active
- 2012-08-08 EP EP12753675.3A patent/EP2741763B1/en active Active
- 2012-08-08 DK DK19213649.7T patent/DK3646881T3/da active
- 2012-08-08 KR KR1020147005938A patent/KR102014469B1/ko active Protection Beyond IP Right Term
- 2012-08-08 KR KR1020217037512A patent/KR102499969B1/ko active IP Right Grant
- 2012-08-08 FI FIEP21207717.6T patent/FI4005588T3/fi active
- 2012-08-08 RS RS20181263A patent/RS57897B1/sr unknown
- 2012-08-08 HU HUE17154031A patent/HUE040058T2/hu unknown
-
2014
- 2014-01-28 IL IL230696A patent/IL230696B2/en unknown
- 2014-02-06 MX MX2020010991A patent/MX2020010991A/es unknown
- 2014-02-07 ZA ZA2014/00952A patent/ZA201400952B/en unknown
- 2014-11-17 HK HK15105458.7A patent/HK1204923A1/xx unknown
- 2014-11-17 HK HK14111597.8A patent/HK1198005A1/zh unknown
-
2015
- 2015-09-01 ZA ZA2015/06382A patent/ZA201506382B/en unknown
-
2016
- 2016-02-09 HR HRP20160145TT patent/HRP20160145T1/hr unknown
- 2016-02-10 SM SM201600038T patent/SMT201600038B/it unknown
- 2016-02-18 CY CY20161100142T patent/CY1117214T1/el unknown
- 2016-12-15 AU AU2016273925A patent/AU2016273925B2/en active Active
-
2017
- 2017-03-16 JP JP2017051062A patent/JP6500050B2/ja active Active
- 2017-06-29 US US15/637,962 patent/US10624953B2/en active Active
-
2018
- 2018-05-09 AU AU2018203222A patent/AU2018203222B2/en active Active
- 2018-10-10 HR HRP20181639TT patent/HRP20181639T1/hr unknown
- 2018-12-27 JP JP2018243912A patent/JP6718951B2/ja active Active
-
2019
- 2019-01-03 HR HRP20190023TT patent/HRP20190023T1/hr unknown
- 2019-08-08 HR HRP20191437 patent/HRP20191437T1/hr unknown
-
2020
- 2020-04-17 US US16/851,260 patent/US11291708B2/en active Active
- 2020-06-15 JP JP2020102938A patent/JP7309660B2/ja active Active
-
2021
- 2021-02-18 HR HRP20210277TT patent/HRP20210277T1/hr unknown
- 2021-05-10 HR HRP20210722TT patent/HRP20210722T1/hr unknown
-
2022
- 2022-03-30 US US17/709,305 patent/US20220370567A1/en active Pending
-
2023
- 2023-07-05 JP JP2023110411A patent/JP2023134561A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210277T1 (hr) | Pripravak za kontroliranu stimulaciju jajnika | |
| HRP20171446T1 (hr) | Topikalni antimikrobni dermatološki pripravak | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| NZ767295A (en) | Liquid inhalation formulation comprising rpl554 | |
| EA201890196A1 (ru) | Композиция для устранения заложенности носа, обладающая противовирусным действием | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| WO2013186777A3 (en) | Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases | |
| MX354828B (es) | Polvos secos de cationes metálicos monovalentes para inhalación. | |
| MX2011014025A (es) | Composicion farmaceutica que comprende sales de rotigotina (acidio o na), especialmente para iontoforesis. | |
| JP2016534142A5 (hr) | ||
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| HRP20240050T1 (hr) | Formulacije tpp1 i postupci liječenja bolesti cln2 | |
| MX2016014346A (es) | Tratamiento de enfermedad de crohn con 6-mercaptopurina de liberacion prolongada. | |
| HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba | |
| WO2015051001A3 (en) | Composition and method for therapeutic agent delivery during pregnancy | |
| EA201800266A1 (ru) | Антивирусная фармацевтическая композиция | |
| BR112015014092A2 (pt) | administração oral transmucosal de acetato de glatirâmer | |
| HRP20211308T1 (hr) | Veterinarski postupak za izazivanje emeze | |
| BR112015014137A2 (pt) | unidade sólida com alto teor de fexofenadina e processo para a preparação da mesma | |
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| BR112019004210A2 (pt) | composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| IL272763B2 (en) | The composition for controlled stimulation of the ovary | |
| MX2017004633A (es) | Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas. | |
| AR107949A1 (es) | ADELMIDROL PARA USO EN ENFERMEDADES CARACTERIZADAS POR AGONISMO INSUFICIENTE DEL RECEPTOR PPAR-g |